Meeting
2014 ASCO Annual Meeting
Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer.
Authors
Francisco Emilio Vera-Badillo
Princess Margaret Cancer Centre - University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada
Francisco Emilio Vera-Badillo , Martin Chang , Gordana Kuruzar , Alberto Ocana , Arnoud J. Templeton , Bostjan Seruga , Mustafa Al-Mubarak , Robyn Goldstein , Philippe L. Bedard , Ian Tannock , Eitan Amir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 547)
DOI
10.1200/jco.2014.32.15_suppl.547
Abstract #
547
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei